David W. Andrews
0000-0002-9266-7157
Publication & Citation Trends
Publications
0 total
Neurobiological pathways underlying brain tumor progression: basis for oncogenicity and opportunities for immunotherapeutic intervention
Cited by 0
Semantic Scholar
Broad applicability of the Goldspire™ platform for the treatment of solid tumors.
Cited by 1
Semantic Scholar
P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Cited by 0
Semantic Scholar
CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Cited by 0
Semantic Scholar
CTIM-11. LONG-TERM SURVIVORS FROM A PHASE 1B STUDY OF IGV-001 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Cited by 0
Semantic Scholar
Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy OA
Cited by 0
Semantic Scholar
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
Cited by 4
Semantic Scholar
RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS OA
Cited by 0
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(153)
Brain Metastases and Treatment
(99)
Meningioma and schwannoma management
(91)
Cell death mechanisms and regulation
(86)
RNA Interference and Gene Delivery
(56)
Affiliations
The Wistar Institute
AstraZeneca (United Kingdom)
Northwestern University
Ontario Institute for Cancer Research
University of North Texas